

Fawziah Marra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3001431/publications.pdf>

Version: 2024-02-01

53
papers

1,378
citations

361413

20
h-index

345221

36
g-index

53
all docs

53
docs citations

53
times ranked

1961
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibiotic Use in Children Is Associated With Increased Risk of Asthma. <i>Pediatrics</i> , 2009, 123, 1003-1010.	2.1	244
2	Risk Factors for Herpes Zoster Infection: A Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa005.	0.9	124
3	The use and misuse of antibiotics in dentistry. <i>Journal of the American Dental Association</i> , 2018, 149, 869-884.e5.	1.5	78
4	Impact of pharmacist administration of influenza vaccines on uptake in Canada. <i>Cmaj</i> , 2017, 189, E146-E152.	2.0	71
5	Health-Related Quality of Life Trajectories Among Adults With Tuberculosis. <i>Chest</i> , 2008, 133, 396-403.	0.8	70
6	Health State Utilities in Latent and Active Tuberculosis. <i>Value in Health</i> , 2008, 11, 1154-1161.	0.3	62
7	A Systematic Review on TST and IGRA Tests Used for Diagnosis of LTBI in Immigrants. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 9-24.	3.8	50
8	Impact of the 13-Valent Pneumococcal Conjugate Vaccine Among Adults: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2019, 69, 34-49.	5.8	44
9	Increasing incidence associated with herpes zoster infection in British Columbia, Canada. <i>BMC Infectious Diseases</i> , 2016, 16, 589.	2.9	43
10	A meta-analysis of stroke risk following herpes zoster infection. <i>BMC Infectious Diseases</i> , 2017, 17, 198.	2.9	40
11	Evaluation of the Do Bugs Need Drugs? Program in British Columbia: Can We Curb Antibiotic Prescribing?. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2011, 22, 19-24.	1.9	39
12	Systematic Review of the Treatment of Early Lyme Disease. <i>Drugs</i> , 1999, 57, 157-173.	10.9	31
13	Latent Tuberculosis Infection Screening in Immigrants to Low-Incidence Countries: A Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 107-117.	3.8	30
14	Estimated Impact of World Health Organization Latent Tuberculosis Screening Guidelines in a Region With a Low Tuberculosis Incidence: Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 2101-2108.	5.8	26
15	The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial. <i>European Respiratory Journal</i> , 2018, 51, 1701488.	6.7	25
16	Demographic predictors of active tuberculosis in people migrating to British Columbia, Canada: a retrospective cohort study. <i>Cmaj</i> , 2018, 190, E209-E216.	2.0	24
17	The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2020, 99, 204-213.	3.3	24
18	Amphotericin B Disposition after Aerosol Inhalation in Lung Transplant Recipients. <i>Annals of Pharmacotherapy</i> , 2002, 36, 46-51.	1.9	23

#	ARTICLE	IF	CITATIONS
19	Testing the External Validity of a Discrete Choice Experiment Method: An Application to Latent Tuberculosis Infection Treatment. <i>Value in Health</i> , 2017, 20, 969-975.	0.3	22
20	A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 325-340.	2.1	21
21	Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis. <i>Vaccine</i> , 2019, 37, 1021-1029.	3.8	21
22	A New Ciprofloxacin Stepdown Program in the Treatment of High-Risk Febrile Neutropenia: A Clinical and Economic Analysis. <i>Pharmacotherapy</i> , 2000, 20, 931-940.	2.6	20
23	Role of Therapeutic Drug Monitoring for Protease Inhibitors. <i>Annals of Pharmacotherapy</i> , 2001, 35, 745-754.	1.9	20
24	Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study. <i>BMJ Open</i> , 2017, 7, e015108.	1.9	20
25	Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries. <i>Emerging Infectious Diseases</i> , 2019, 25, 661-671.	4.3	19
26	Review of Evidence for Measuring Drug Concentrations of First-Line Antitubercular Agents in Adults. <i>Clinical Pharmacokinetics</i> , 2014, 53, 873-890.	3.5	18
27	Utilization of Antibiotics in Long-Term Care Facilities in British Columbia, Canada. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 1098.e1-1098.e11.	2.5	18
28	Effect of formulary policy decisions on antimicrobial drug utilization in British Columbia. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 95-101.	3.0	17
29	Cost-Effectiveness of LTBI Treatment for TB Contacts in British Columbia. <i>Value in Health</i> , 2008, 11, 842-852.	0.3	15
30	Predicting tuberculosis risk in the foreign-born population of British Columbia, Canada: study protocol for a retrospective population-based cohort study. <i>BMJ Open</i> , 2016, 6, e013488.	1.9	15
31	Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada. <i>PLoS ONE</i> , 2017, 12, e0186778.	2.5	15
32	Screening immigrants for latent tuberculosis: Do we have the resources?. <i>Cmaj</i> , 2014, 186, 246-247.	2.0	12
33	Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis. <i>American Journal of Kidney Diseases</i> , 2019, 73, 39-50.	1.9	11
34	Impact of the 13-valent pneumococcal conjugate vaccine on acute otitis media and acute sinusitis epidemiology in British Columbia, Canada. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2419-2427.	3.0	9
35	Outpatient antibiotic use in British Columbia, Canada: reviewing major trends since 2000. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab116.	2.1	9
36	Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection. <i>Drugs</i> , 2015, 75, 1095-1118.	10.9	8

#	ARTICLE	IF	CITATIONS
37	Characterization of Clostridium difficile Strains in British Columbia, Canada: A Shift from NAP1 Majority (2008) to Novel Strain Types (2013) in One Region. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-8.	1.9	8
38	Incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate pneumococcal vaccine in British Columbia: A retrospective cohort study. PLoS ONE, 2020, 15, e0239848.	2.5	8
39	Cost-benefit analysis of a population-based education program on the wise use of antibiotics. Canadian Journal of Public Health, 2019, 110, 732-740.	2.3	7
40	Population-based incidence of invasive pneumococcal disease in children and adults in Ontario and British Columbia, 2002-2018: A Canadian Immunization Research Network (CIRN) study. Vaccine, 2021, 39, 7545-7553.	3.8	5
41	Quantifying the Gap between Expected and Actual Rates of Antibiotic Prescribing in British Columbia, Canada. Antibiotics, 2021, 10, 1428.	3.7	3
42	A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada. Vaccine, 2022, 40, 1047-1053.	3.8	3
43	Appropriateness of Outpatient Antibiotic Use in Seniors across Two Canadian Provinces. Antibiotics, 2021, 10, 1484.	3.7	3
44	Increasing paediatric prescribing rates in British Columbian children: cause for concern?. Canadian Journal of Public Health, 2020, 111, 523-530.	2.3	2
45	A Decrease in Antibiotic Utilization for Urinary Tract Infections in Women in Long-Term Care Facilities. Canadian Geriatrics Journal, 2018, 21, 262-263.	1.2	1
46	Increased Moxifloxacin Utilization Associated with an Unrestricted Addition to a Drug Reimbursement Formulary: A Population-Based Analysis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 27-31.	1.9	0
47	Healthcare Costs for Pneumococcal Disease in the Era of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine: A Population-Based Study. Value in Health, 2022, , .	0.3	0
48	Title is missing!. , 2020, 15, e0239848.		0
49	Title is missing!. , 2020, 15, e0239848.		0
50	Title is missing!. , 2020, 15, e0239848.		0
51	Title is missing!. , 2020, 15, e0239848.		0
52	Title is missing!. , 2020, 15, e0239848.		0
53	Title is missing!. , 2020, 15, e0239848.		0